Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr;8(2):100778.
doi: 10.1016/j.esmoop.2022.100778. Epub 2023 Feb 13.

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

S J Klempner  1 , Y Y Janjigian  2 , Z A Wainberg  3
Affiliations
Editorial

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

S J Klempner et al. ESMO Open. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure SJK reports consulting/advisory role in Eli Lilly, Merck, BMS, Novartis, Astellas, AstraZeneca, Daiichi-Sankyo, Novartis, Sanofi-Aventis, Natera, Exact Sciences, and Mersana; stock/equity in Turning Point Therapeutics and Nuvalent. YYJ reports consulting/advisory role in AmerisourceBergen Corporation, Arcus Biosciences, Inc., AstraZeneca, Axis Medical Education, Basilea Pharmaceutica International Ltd., Bristol-Myers Squibb, Clinical Care Options, Creative Educational Concepts, Inc., Daiichi Sankyo, Eli Lilly and Company, Geneos Therapeutics, Inc., GlaxoSmithKline, Imedex, Inc., Lynx Health LLC, Merck & Co Inc., Michael J. Hennessy Associates, PeerView Institute for Medical Education (PVI), Prova Education, Inc., Research to Practice, Rgenix (Ownership/Equity Interests), and Silverback Therapeutics, Inc. ZAW reports consulting for Amgen, Arcus, Astra Zeneca, Daiichi, Bayer, BMS, Merck, Ipsen, Lilly, Gilead, Arcus, Astellas, and Molecular Templates; and research grants from Arcus, BMS, and Plexxikon.

Figures

Figure 1
Figure 1
Potential future biomarker testing in advanced gastroesophageal adenocarcinomas. Current approaches rely on individual immunohistochemical tests for MMR assessment, HER2 testing, and PD-L1 CPS testing. CLDN18.2 and FGFR2b are emerging biomarkers utilizing IHC platforms. Molecular alterations detectable by tissue and/or plasma-based next-generation sequencing are shown on the right. amp, amplification; CPS, combined positive score; EGFR, epidermal growth factor receptor; ERBB2, Erb-B2 Receptor Tyrosine Kinase; FGFR2b, fibroblast growth factor receptor 2b; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; MET, MET proto-oncogene, receptor tyrosine kinase; MMR, mismatch repair; MSI, microsatellite instability; NTRK, neurotrophic receptor tyrosine kinase; PD-L1, programmed death-ligand 1; TMB, tumor mutation burden.
See this image and copyright information in PMC

Comment on

References

    1. Janjigian Y.Y., Shitara K., Moehler M., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. - PMC - PubMed
    1. Janjigian Y.Y., Kawazoe A., Yañez P., et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730. - PMC - PubMed
    1. Wainberg Z.A., Enzinger P.C., Kang Y.K., et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430–1440. - PubMed
    1. Kubota Y., Kawazoe A., Mishima S., et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023 In press. - PMC - PubMed
    1. Pellino A., Brignola S., Riello E., et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med. 2021;11:1095. - PMC - PubMed